🇺🇸 FDA
Patent

US 11466010

Toll-like receptor 8 (TLR8) specific antagonists and methods of making and uses thereof

granted A61KA61K31/47A61K31/4709

Quick answer

US patent 11466010 (Toll-like receptor 8 (TLR8) specific antagonists and methods of making and uses thereof) held by The Regents of the University of Colorado, a Body Corporate expires Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of Colorado, a Body Corporate
Grant date
Tue Oct 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K31/47, A61K31/4709, A61K31/502, A61K31/519